Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
386 results about "Piperidine derivative" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
4-substituted piperidine derivatives
ActiveUS7572913B2Promote neurite outgrowthPotential curative effectAntibacterial agentsBiocideDiseaseCell membrane
Substituted piperidine compounds represented by the structure I are provided,wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
Owner:BIOAXONE BIOSCI
4-Substituted piperidine derivatives
ActiveUS20050272751A1Promote neurite outgrowthPotential curative effectAntibacterial agentsBiocideDiseaseNervous system
Substituted piperidine compounds represented by the structure I are provided, wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.
Owner:BIOAXONE BIOSCI
N-substituted piperidine derivatives as serotonin receptor agents
InactiveUS20060094758A1Inhibitory activityInhibition of activationBiocideOrganic chemistry5-HT receptorBiological activation
Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.
Owner:ACADIA PHARMA INC
1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
Compound of the formula (I):wherein Ar is a group of the following formula (Ar-1) or (Ar-2):A is a group of the formula:oror a pharmaceutically acceptable acid addition salt thereof, a process for preparing the same, a pharmaceutical composition containing the same, and intermediates therefor. The compounds of the present invention show a potent affinity for 5-HT4 receptors, and they are useful as a gastrointestinal motility enhancer or a gastrointestinal prokinetic agent.
![1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds](https://images-eureka.patsnap.com/patent_img/28d03f29-53ab-4386-8536-d9480a8dfdd1/US06294555-20010925-C00001.png "1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds")
![1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds](https://images-eureka.patsnap.com/patent_img/28d03f29-53ab-4386-8536-d9480a8dfdd1/US06294555-20010925-C00002.png "1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds")
![1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds](https://images-eureka.patsnap.com/patent_img/28d03f29-53ab-4386-8536-d9480a8dfdd1/US06294555-20010925-C00003.png "1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds")
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
N-substituted piperidine derivatives as serotonin receptor agents
Owner:ACADIA PHARMA INC
Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
InactiveUS20060194780A1Reduce usageUseful in treatmentBiocideNervous disorderSexual impotenceSexual dysfunction
Certain novel bicyclic N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
Owner:MERCK SHARP & DOHME CORP
N-substituted piperidine derivatives as serotonin receptor agents
InactiveUS20060199818A1Inhibitory activityInhibition of activationBiocideNervous disorderCompound (substance)Biological activation
Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.
Owner:ACADIA PHARMA INC
N-substituted piperidine derivatives as serotonin receptor agents
InactiveUS7253186B2Inhibitory activityInhibition of activationBiocideOrganic chemistry5-HT receptorBiological activation
Disclosed herein are compounds of Formula I,or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.
Owner:ACADIA PHARMA INC
Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
InactiveUS20070066590A1Reduce weight gainLess weight gainBiocideOrganic chemistryChemistryPiperidine derivative
The present invention relates to certain substituted aryl and heteroaryl derivatives as shown in Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
Owner:ARENA PHARMA
Piperidine derivatives
Owner:AMGEN INC
Hydroxy piperidine derivatives to treat gaucher disease
The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.
Owner:AMICUS THERAPEUTICS INC
Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
InactiveUS20060183904A1Reduce usageUseful in treatmentBiocideOrganic chemistrySexual impotenceSexual dysfunction
Certain novel N-acylated spiropiperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
Owner:MERCK SHARP & DOHME CORP
Piperidine derivatives
Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and / or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.
Owner:AMGEN INC
Fluorides of 4-substituted piperidine derivatives
The present invention provides a novel compound having an excellent acetylcholinesterase inhibitory effect. That is, it provides a 4-substituted piperidine compound fluoride represented by the following formula, a pharmaceutically acceptable salt thereof or hydrates thereof (provided that 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine, a pharmaceutically acceptable salt thereof and hydrates thereof are excluded).wherein R<1 >and R<2 >represent substituents.
Owner:EISIA R&D MANAGEMENT CO LTD
Pyridine and piperidine derivatives and use thereof
The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I:or pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein R1, R4, X, G, n, p, W1, W2, W3, W4, and the E ring are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II-XIII as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.
Owner:PURDUE PHARMA LP
Diketo-piperazine and piperidine derivatives as antiviral agents
ActiveUS20070249579A1Useful in treatmentBiocideOrganic chemistryPiperazineHuman immunodeficiency virus (HIV)
This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Diketo-piperazine and piperidine derivatives as antiviral agents
This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Piperidine derivatives and methods of use
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Owner:CHEMOCENTRYX INC
N-substituted piperidine derivatives as serotonin receptor agents
InactiveUS20090082342A1Reducing level of prolactinLower Level RequirementsBiocideNervous disorderDiseaseSide effect
Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.
Owner:ACADIA PHARMA INC
Novel compounds
InactiveUS20100160344A1Improve oral bioavailabilityImprove solubilityBiocideOrganic active ingredientsCombinatorial chemistryPharmaceutical Substances
This invention relates to imidazopyrimidine substituted piperidine derivatives and their use as pharmaceuticals.
Owner:GLAXO GROUP LTD
Novel compounds
InactiveUS20100160345A1Improve oral bioavailabilityMaintain good propertiesBiocideNervous disorderPiperidine derivativeImidazole
This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals.
Owner:GLAXO GROUP LTD
4,4-disubstituted piperidine derivatives
This invention relates to 4,4-disubstituted piperidine derivatives of the formulawherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and / or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
Owner:F HOFFMANN LA ROCHE & CO AG
Acylated piperidine derivatives as melanocortin-4 receptor agonists
InactiveUS20040092501A1Minimize formationReduce appetiteBiocideMetabolism disorderDiseaseSexual dysfunction
Owner:MERCK SHARP & DOHME CORP
Piperidine derivatives and methods of treating hepatitis B infections
ActiveUS9400280B2Reduce loadReduce incidenceOrganic chemistryHeterocyclic compound active ingredientsMedicineHepatitis B
Owner:NOVIRA THERAPEUTICS
Novel piperidine derivative
InactiveUS20070078120A1Increase heightRegulating LDL receptor synthesisBiocideOrganic chemistryHydrogen atomLipoproteins Receptors
The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4, R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Piperidine derivatives useful as CCR5 antagonists
Owner:SCHERING CORP
N-substituted piperidine derivatives as serotonin receptor agents
Owner:ACADIA PHARMA INC
Piperazinylpiperidine derivatives as chemokine receptor antagonists
ActiveUS20050261310A1Improve actionReduce releaseSilicon organic compoundsOrganic active ingredientsChemokine Receptor AntagonistHIV receptor
The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
Owner:INCYTE HLDG CORP
Piperidine derivatives useful as CCR5 antagonists
The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R<1>, R<2>, R<3>, R<9>, R<10>, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
Owner:SCHERING CORP
Piperidine derivatives and methods of use
Owner:CHEMOCENTRYX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com